Is TMDX a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for TransMedics Group (TMDX) rests on OCS adoption and DCD organ expansion: The Organ Care System lets transplant centers use organs, including those from donors after circulatory death, that ice-based cold storage often cannot preserve well enough to transplant. Revenue (TTM) is ~$636M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: TransMedics depends heavily on the OCS platform and its National OCS Program, so any slowdown in transplant volumes, reimbursement changes, or clinical setbacks would hit results directly. Whether TMDX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
TransMedics Group is a commercial-stage medical-technology company built around the Organ Care System (OCS), a portable device that perfuses donor organs with warm oxygenated blood to keep them functioning and assessable outside the body, an alternative to keeping organs on ice. It has FDA approval for OCS Heart, OCS Liver, and OCS Lung, including organs recovered from donors after circulatory death (DCD), which meaningfully expands the pool of usable organs. On top of the devices, TransMedics has built a National OCS Program (NOP) that provides organ retrieval surgeons, ground transport, and a growing owned aviation fleet, so the company now earns both product revenue from disposables and service revenue from logistics. The investment picture is a high-growth story with execution and margin questions attached. Revenue reached about $605 million in 2025 and grew roughly 21% year over year in the first quarter of 2026, and management guides to $727 million to $757 million for full-year 2026. The counterweight is that heavy spending on logistics, aviation, research, and next-generation products has compressed gross and operating margins, quarterly earnings have missed analyst expectations, and the stock fell sharply from 2025 highs above $150 to the $70s by mid-2026. For investors, TMDX is a higher-volatility bet on continued OCS adoption, the planned OCS Kidney launch, and whether growth investments eventually translate into durable profitability.
What's the case for buying TMDX?
1. OCS adoption and DCD organ expansion
The Organ Care System lets transplant centers use organs, including those from donors after circulatory death, that ice-based cold storage often cannot preserve well enough to transplant. That expands the usable donor pool for hearts, livers, and lungs. Rising OCS case volumes across all three approved organs is the core engine driving revenue growth above 20%.
2. National OCS Program and owned logistics
TransMedics has built a National OCS Program that bundles organ-retrieval surgeons, ground transport, and aircraft, capturing service revenue on top of device sales. The company announced an investment in PAD Aviation, a Germany-based private-aviation operator, to build a dedicated organ-transport network. Owning more of the logistics chain deepens the moat but also raises operating costs and capital intensity.
3. OCS Kidney and new indications
Kidneys are the largest solid-organ transplant category by volume, and TransMedics is developing OCS Kidney with a launch targeted for late 2026 or early 2027. Success there would open the biggest remaining part of its addressable market. European expansion, including Italy, is a further geographic growth lever management has highlighted.
4. Path from growth to profitability
First-quarter 2026 net income was about $7.3 million on revenue of roughly $174 million, so the company is profitable but at thin and shrinking margins as it reinvests. Gross margin slipped to about 58% from 61% a year earlier while operating expenses rose sharply. Whether scale eventually lifts margins is central to how the market values the stock.
What are the risks to TMDX?
TransMedics depends heavily on the OCS platform and its National OCS Program, so any slowdown in transplant volumes, reimbursement changes, or clinical setbacks would hit results directly. Margins have compressed as the company spends aggressively on logistics, aviation, and research, and quarterly adjusted earnings have missed analyst expectations, contributing to a sharp drop from 2025 highs. The company has flagged an identified material weakness in internal controls in past filings and carries 1.50% convertible notes due 2028 that add financing risk. Its growing dominance in organ perfusion could invite antitrust or competitive scrutiny, and next-generation products like OCS Kidney face clinical-trial and regulatory uncertainty. The stock is volatile and richly valued relative to current earnings, so disappointments can trigger large moves.
How is TMDX valued? (as of JULY 2026)
Snapshot for TMDX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$636M
- Q1 2026 revenue: ~$173.9M (+21% YoY)
- FY2026 revenue guidance: ~$727M to $757M (20-25% growth)
- Q1 2026 gross margin: ~58% (down from ~61%)
- Cash and equivalents: ~$462M
- Market cap: ~$2.6B
TransMedics traded around $76 in mid-July 2026, well below its 52-week high near $156 and closer to its low around $60, reflecting a large re-rating after margin pressure and earnings misses. The company remains profitable but thinly so, which makes valuation multiples sensitive to which earnings measure is used. The stock is priced as a high-growth medical-technology name, so continued 20%-plus revenue growth is largely an expectation rather than a cushion.
How do you decide if TMDX is a buy?
Rather than asking whether TMDX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold TMDX indirectly through an index or sector ETF before adding more.
For the full picture, see the TMDX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TMDX against your real portfolio and see your actual exposure before deciding.
The bottom line on TMDX
The bottom line: TransMedics Group's story right now is OCS adoption and DCD organ expansion, with revenue (ttm) at ~$636M. If you believe that narrative continues, the call is about sizing TMDX sensibly and checking overlap with what you own; if you doubt it (the risk: transMedics depends heavily on the OCS platform and its National OCS Program, so any slowdown in transplant volumes, reimbursement changes, or clinical setbacks would hit results directly.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around TMDX with Walnut
Use TransMedics Group as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TMDX a good stock to buy right now?
+
The case for TransMedics Group right now is OCS adoption and DCD organ expansion, with revenue (ttm) at ~$636M. If you believe that thesis holds, TMDX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is transMedics depends heavily on the OCS platform and its National OCS Program, so any slowdown in transplant volumes, reimbursement changes, or clinical setbacks would hit results directly. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does TransMedics Group do?
+
TransMedics Group is a commercial-stage medical-technology company built around the Organ Care System (OCS), a portable device that perfuses donor organs with warm oxygenated blood
What are the main risks of TMDX?
+
TransMedics depends heavily on the OCS platform and its National OCS Program, so any slowdown in transplant volumes, reimbursement changes, or clinical setbacks would hit results directly. Margins have compressed as the company spends aggressively on logistics, aviation, and research, and quarterly adjusted earnings have missed analyst expectations, contributing to a sharp drop from 2025 highs. The company has flagged an identified material weakness in internal controls in past filings and carries 1.50% convertible notes due 2028 that add financing risk. Its growing dominance in organ perfusion could invite antitrust or competitive scrutiny, and next-generation products like OCS Kidney face clinical-trial and regulatory uncertainty. The stock is volatile and richly valued relative to current earnings, so disappointments can trigger large moves.
What does TransMedics do?
+
TransMedics makes the Organ Care System (OCS), a portable device that keeps donor hearts, livers, and lungs functioning with warm oxygenated blood outside the body instead of on ice. It also runs a National OCS Program that provides retrieval surgeons, ground transport, and aircraft to move organs to transplant centers.
Is TMDX profitable?
+
TransMedics is profitable but at thin margins. It reported net income of about $7.3 million on roughly $174 million of revenue in the first quarter of 2026, with gross margin around 58%, down from a year earlier as spending on logistics, aviation, and research rose faster than revenue.
Why did TMDX stock fall so much?
+
The shares dropped from 2025 highs above $150 to the $70s by mid-2026 after margins compressed and adjusted earnings missed analyst expectations. The company is spending heavily to build out logistics and next-generation products, which squeezed profitability even as revenue kept growing above 20%.
What is the OCS and why does it matter?
+
The Organ Care System perfuses donor organs with warm blood so they keep functioning and can be assessed outside the body. This can preserve organs, including those from donors after circulatory death, that traditional cold storage cannot, which expands the pool of transplantable organs.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell TMDX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.